tk216
Small moleculeexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2016 (NCT02657005)
Timeline
Indications
Mechanism of action
- EWS-Fli1 proteinINHIBITOR
EWS-Fli1 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- tk216
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05046314 | Phase 2 | Dec 1, 2021 | Jiao Tong University, Shanghai Pharmaceuticals Holding Co., Ltd |
| NCT03752138 | Phase 1 | Mar 31, 2019 | National Cancer Institute (NCI), University of Texas at Houston |
| NCT02657005 | Phase 1 | May 1, 2016 | Oncternal Therapeutics |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Jiao Tong University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2019 |
| Oncternal Therapeutics | For profit | 1 | 1 | 1 | 2016 |
| Shanghai Pharmaceuticals Holding Co., Ltd | For profit | 1 | 1 | 1 | 2021 |
| University of Texas at Houston | Academic/Hospital | 1 | 1 | 1 | 2019 |
5 organizations
Page 1 / 1